Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

FG Trade/E+ via Getty Images The last time I wrote about Viridian Therapeutics, Inc. (VRDN) it was in a Seeking Alpha article entitled "Viridian: Despite Drop, Advancement Towards Phase 3 continues." At that time, I noted that data from the THRIVE phase 3 study using veligrotug [VRDN-001] for the treatment of patients with active thyroid eye disease [TED], would be released around mid-2024. I'm happy to state that the company just released data showing that this drug was able to meet the primary endpoint of ...